Nilvadipine
 | |
| Systematic (IUPAC) name | |
|---|---|
| 5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Identifiers | |
 | |
| C08CA10 | |
| PubChem | CID 4494 |
| DrugBank |
DB06712 |
| ChemSpider |
4338  |
| UNII |
0214FUT37J |
| KEGG |
D01908 |
| ChEMBL |
CHEMBL517427 |
| Chemical data | |
| Formula | C19H19N3O6 |
| 385.370 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Nilvadipine is a calcium channel blocker (CCB) used for the treatment of hypertension and chronic major cerebral artery occlusion.
Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.
Nilvadipine was tested in clinical trial as a possible treatment for Alzheimer's Disease in Ireland by the Roskamp Institute, Florida, USA and Trinity College, Ireland.[1]
Following this study, an international research consortium led by Trinity College Dublin (Ireland) in May 2011 announced the selection for funding of a large-scale European clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute in Sarasota. More than 500 Alzheimer’s patients will participate in the multicenter Phase III clinical trial designed to study the effectiveness of Nilvadipine.[2]